Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combination of perindopril 10 mg, indapamide 2.5 mg and amlodipine 5 or 10 mg in patients with uncontrolled essential hypertension. An international, multicentre, randomised, double-blind, 16-week study
Latest Information Update: 25 Mar 2024
At a glance
- Drugs Amlodipine/bisoprolol/indapamide/perindopril (Primary) ; Amlodipine; Indapamide; Perindopril
- Indications Essential hypertension
- Focus Therapeutic Use
- 17 Mar 2024 Status changed from recruiting to completed.
- 07 Feb 2024 This trial has been completed in Latvia (Global end date: 14 Dec 2023).
- 13 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.